1098184-03-2

Usage

Uses

Used in Pharmaceutical Industry:
(S)-N-Boc-4,4,4,4,4,4-Hexafluorovaline is used as a building block for the development of peptide-based drugs. (S)-N-Boc-4,4,4,4,4,4-Hexafluorovaline's unique properties, such as increased metabolic stability and improved bioavailability, make it an attractive option for the design and synthesis of novel therapeutic agents.
Used in Peptide Synthesis:
In the field of peptide synthesis, (S)-N-Boc-4,4,4,4,4,4-Hexafluorovaline serves as a valuable component for the creation of novel peptide sequences. The fluorine substituents in the compound can lead to altered binding affinities and specific interactions with biological targets, making it a useful tool for the development of new peptides with tailored properties.
Used in Chemical Biology Research:
(S)-N-Boc-4,4,4,4,4,4-Hexafluorovaline is also utilized in chemical biology research, where it can be employed to study the effects of fluorination on protein structure and function. (S)-N-Boc-4,4,4,4,4,4-Hexafluorovaline's unique properties can provide insights into the role of fluorine in biological systems and contribute to the development of new strategies for drug design and target identification.

Upstream product

• 34619-03-9 tert-butyldicarbonate 
• 16063-80-2 (RS)-hexafluorovaline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1513-60-6 ethyl 4,4,4-trifluoro-3-(trifluoromethyl)crotonate 
• 107496-46-8 N^α-(tert-butyloxycarbonyl)-DL-hexafluorovaline 
• 149560-62-3 4,4,4,4',4',4'-hexafluoro-DL-valine 
• 107496-44-6 benzyl 4,4,4-trifluoro-3-(trifluoromethyl)but-2-enoate 
• 107496-45-7 DL-hexafluorovaline benzyl ester 
• 78185-92-9 DL-Hfv-OEt 

Relevant academic research and scientific papers

Methyl to trifluoromethyl substitution as a strategy to increase the membrane permeability of short peptides

Here, we investigated the effect of CH3to CF3substitution on the membrane permeability of peptides. We synthesized a series of peptides with CF3groups and corresponding nonfluorinated peptides and measured the membrane per

METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS

Disclosed are methods for synergistically inhibiting the proliferation of tumor cells by contacting the tumor cells with a MEK inhibitor compound and erlotinib, either sequentially or simultaneously. Also disclosed are methods for inhibiting the proliferation of tumor cells in a human, by administering to the human, sequentially or simultaneously, an amount of erlotinib and a MEK inhibitor compound, wherein the amounts are effective, in combination, to synergistically inhibit the proliferation of the tumor cells in the human.

Substituted hydantoins

The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.

Synthesis of [Hexafluorovalyl1,1′]gramicidin S

[Hexafluorovalyl1,1′]gramicidin S (8), in which two valine residues in the natural gramicidin S were replaced by L-hexafluorovaline (Hfv) residues, was synthesized by the solid-phase-synthesis and cyclization-cleavage method on benzophenone oxime resin. Though the racemic hexafluorovaline derivative was employed for the peptide synthesis, the desired product was isolated in moderate yield, probably reflecting the stable cyclic structure of 8. CD and 1HNMR spectra indicated that the conformation of 8 is similar to that of gramicidin S. The two β-turn structure and antiparallel β-sheet structure with four intramolecular hydrogen bondings were maintained in spite of introducing the hexafluorovaline residues. The dye-release experiment from lecithin vesicle and antimacrobial activity assay also indicated that 8 showed membrane-disturbing activity like gramicidin S, although the activity of 8 was somewhat weaker than gramicidin S.